BNP Paribas Financial Markets
EWTX icon

BNP Paribas Financial Markets’s Edgewise Therapeutics EWTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
43,587
+19,676
+82% +$678K ﹤0.01% 2894
2026
Q1 		$753K Buy
23,911
+6,850
+40% +$198K ﹤0.01% 3338
2025
Q4 		$423K Buy
17,061
+2,764
+19% +$55.5K ﹤0.01% 3660
2025
Q3 		$232K Buy
14,297
+6,104
+75% +$86.6K ﹤0.01% 3939
2025
Q2 		$107K Buy
8,193
+2,689
+49% +$38.8K ﹤0.01% 3991
2025
Q1 		$121K Sell
5,504
-27,578
-83% -$723K ﹤0.01% 3967
2024
Q4 		$883K Buy
+33,082
New +$1.05M ﹤0.01% 2909

Other funds holding EWTX

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BNP Paribas Financial Markets's EWTX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Edgewise Therapeutics (EWTX) stake by 82% in Q2 2026, buying an estimated $678K and bringing the position to 43,587 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2894.

BNP Paribas Financial Markets first reported a position in EWTX in Q4 2024 and has held it in 7 quarters since. 205 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • BNP Paribas Financial Markets held 43,587 shares of Edgewise Therapeutics worth $1.77M as of Q2 2026.
  • BNP Paribas Financial Markets bought 19,676 Edgewise Therapeutics shares in Q2 2026, an estimated $678K.
  • Edgewise Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2894 holding.
  • BNP Paribas Financial Markets first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 205 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.